Mizuho Nagao1, Takao Fujisawa2, Toshiaki Ihara3, Yoichiro Kino4. 1. Allergy Center, Mie National Hospital, Tsu, Japan. 2. Allergy Center, Mie National Hospital, Tsu, Japan. Electronic address: fujisawa@mie-m.hosp.go.jp. 3. Infectious Disease Center, Mie National Hospital, Tsu, Japan. 4. Chemo-Sero-Therapeutic Research Institute (Kaketsuken), Kumamoto, Japan.
Abstract
BACKGROUND: Influenza vaccines produced in embryonated eggs might pose a risk to patients with egg allergy. However, patients experiencing influenza vaccine-associated anaphylaxis (IVA) do not always have egg allergy. In the 2011-2012 season, an unusually high incidence of IVA was reported in Japan. OBJECTIVE: We sought to identify the cause of the increase in anaphylactic events in 2011-2012 in Japan. METHODS: We collected blood specimens from patients with IVA from all areas of Japan. We analyzed 19 patients with confirmed IVA and 25 age-matched control subjects, including 10 with egg allergy who had no adverse events after corresponding vaccination. ELISA was used to measure specific IgE levels to the trivalent vaccines of several manufacturers and hemagglutinin proteins derived from both egg and cell cultures. Antigen-induced basophil activation was evaluated by measuring CD203c expression by means of flow cytometry. Vaccine excipients were also examined for effects on CD203c expression. RESULTS: None of the patients with IVA had severe egg allergy. Levels of specific IgE antibodies to influenza vaccine antigens, whole-vaccine products from different manufacturers, and hemagglutinin proteins (A H1, H3, and B) derived from both egg and cell cultures were significantly increased in patients with IVA compared with those in control subjects. Influenza vaccine-induced CD203c expression in basophils was also highly enhanced in patients with IVA but not in control subjects. Because IVA was most frequent in patients who received 2-phenoxyethanol (2-PE)-containing vaccine, the effect of this preservative on basophil activation was examined, and the activation was slightly enhanced by 2-PE but not thimerosal. CONCLUSIONS: The 2011-2012 IVA spike in Japan was caused by specific IgE antibodies to influenza vaccine components. Excipients could not be implicated, except for a modest effect of 2-PE.
BACKGROUND: Influenza vaccines produced in embryonated eggs might pose a risk to patients with egg allergy. However, patients experiencing influenza vaccine-associated anaphylaxis (IVA) do not always have egg allergy. In the 2011-2012 season, an unusually high incidence of IVA was reported in Japan. OBJECTIVE: We sought to identify the cause of the increase in anaphylactic events in 2011-2012 in Japan. METHODS: We collected blood specimens from patients with IVA from all areas of Japan. We analyzed 19 patients with confirmed IVA and 25 age-matched control subjects, including 10 with egg allergy who had no adverse events after corresponding vaccination. ELISA was used to measure specific IgE levels to the trivalent vaccines of several manufacturers and hemagglutinin proteins derived from both egg and cell cultures. Antigen-induced basophil activation was evaluated by measuring CD203c expression by means of flow cytometry. Vaccine excipients were also examined for effects on CD203c expression. RESULTS: None of the patients with IVA had severe egg allergy. Levels of specific IgE antibodies to influenza vaccine antigens, whole-vaccine products from different manufacturers, and hemagglutinin proteins (A H1, H3, and B) derived from both egg and cell cultures were significantly increased in patients with IVA compared with those in control subjects. Influenza vaccine-induced CD203c expression in basophils was also highly enhanced in patients with IVA but not in control subjects. Because IVA was most frequent in patients who received 2-phenoxyethanol (2-PE)-containing vaccine, the effect of this preservative on basophil activation was examined, and the activation was slightly enhanced by 2-PE but not thimerosal. CONCLUSIONS: The 2011-2012 IVA spike in Japan was caused by specific IgE antibodies to influenza vaccine components. Excipients could not be implicated, except for a modest effect of 2-PE.
Authors: Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips Journal: Br J Clin Pharmacol Date: 2019-11-05 Impact factor: 4.335
Authors: Lori Garman; Kenneth Smith; Emily E Muns; Cathy A Velte; Christina E Spooner; Melissa E Munroe; A Darise Farris; Michael R Nelson; Renata J M Engler; Judith A James Journal: Clin Vaccine Immunol Date: 2016-08-05
Authors: Pedro Cecílio; Begoña Pérez-Cabezas; Laura Fernández; Javier Moreno; Eugenia Carrillo; José M Requena; Epifanio Fichera; Steven G Reed; Rhea N Coler; Shaden Kamhawi; Fabiano Oliveira; Jesus G Valenzuela; Luigi Gradoni; Reinhard Glueck; Gaurav Gupta; Anabela Cordeiro-da-Silva Journal: PLoS Negl Trop Dis Date: 2017-11-27
Authors: Luana Raposo de Melo Moraes Aps; Marco Aurélio Floriano Piantola; Sara Araujo Pereira; Julia Tavares de Castro; Fernanda Ayane de Oliveira Santos; Luís Carlos de Souza Ferreira Journal: Rev Saude Publica Date: 2018-04-12 Impact factor: 2.106